These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 16856931)

  • 1. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
    Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
    Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma.
    Rossi G; Donisi A; Casari S; Re A; Cadeo G; Carosi G
    Cancer; 1999 Dec; 86(11):2391-7. PubMed ID: 10590382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical significance of serum soluble interleukin-2 receptor level in patients with non-Hodgkin's lymphoma].
    Shimomura Y; Tsurumi H; Sawada M; Yamada T; Hara T; Fukuno K; Goto H; Moriwaki H
    Rinsho Ketsueki; 1999 Aug; 40(8):639-45. PubMed ID: 10496038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.
    Goto H; Tsurumi H; Takemura M; Ino-Shimomura Y; Kasahara S; Sawada M; Yamada T; Hara T; Fukuno K; Goto N; Okuno M; Takami T; Seishima M; Moriwaki H
    J Cancer Res Clin Oncol; 2005 Feb; 131(2):73-9. PubMed ID: 15503137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
    Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
    Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen.
    Nakamura N; Goto N; Tsurumi H; Takemura M; Kanemura N; Kasahara S; Hara T; Yasuda I; Shimizu M; Sawada M; Yamada T; Seishima M; Takami T; Moriwaki H
    Eur J Haematol; 2013 Oct; 91(4):322-31. PubMed ID: 23672298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
    Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
    Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index.
    Lech-Maranda E; Bienvenu J; Broussais-Guillaumot F; Warzocha K; Michallet AS; Robak T; Coiffier B; Salles G
    Arch Immunol Ther Exp (Warsz); 2010 Apr; 58(2):131-41. PubMed ID: 20191326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer.
    Gregorc V; Spreafico A; Floriani I; Colombo B; Ludovini V; Pistola L; Bellezza G; Viganò MG; Villa E; Corti A
    Cancer; 2007 Aug; 110(4):845-53. PubMed ID: 17599769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum values of tumour necrosis factor-alpha and of soluble tumour necrosis factor-R55 in melanoma patients.
    Ocvirk J; Stabuc B; Rudolf Z; Galvani V; Curin-Serbec V
    Melanoma Res; 2000 Jun; 10(3):253-8. PubMed ID: 10890379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma.
    Hentschel N; Krusch M; Kiener PA; Kolb HJ; Salih HR; Schmetzer HM
    Eur J Haematol; 2006 Aug; 77(2):91-101. PubMed ID: 16800841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the international prognostic index in working formulation group A low-grade non-Hodgkin's lymphoma: retrospective analysis of 137 patients from the Gruppo Italiano per lo Studio dei Linfomi registry.
    Stelitano C; Baldini L; Pieresca C; Callea V; Angrilli F; Clò V; Partesotti G; Merli F; Cavanna L; Morabito F; Federico M; Brugiatelli M; Silingardi V
    Haematologica; 2000 Feb; 85(2):154-9. PubMed ID: 10681722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term results of the first Italian Association of Pediatric Hematology and Oncology protocol for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP LNH92).
    Pillon M; Di Tullio MT; Garaventa A; Cesaro S; Putti MC; Favre C; Lippi A; Surico G; Di Cataldo A; D'Amore E; Zanesco L; Rosolen A
    Cancer; 2004 Jul; 101(2):385-94. PubMed ID: 15241838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma.
    Bono P; Teerenhovi L; Joensuu H
    Cancer; 2003 Jun; 97(11):2767-75. PubMed ID: 12767089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical significance of immunophenotype in diffuse non-Hodgkin's lymphoma: with special emphasis on the clinical characteristics of T-cell lymphoma].
    Chubachi A; Miura AB; Takatsu H; Yamaguchi A; Nishimura S; Nakayama Y; Akihama T; Miura S; Saitoh M; Watanuki T
    Gan To Kagaku Ryoho; 1991 Jul; 18(8):1303-9. PubMed ID: 2069401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-Hodgkin lymphoma in elderly patients: experience at Taipei Veterans General Hospital.
    Bai LY; Yang MH; Chiou TJ; Liu JH; Yen CC; Wang WS; Hsiao LT; Chao TC; Chen PM
    Cancer; 2003 Sep; 98(6):1188-95. PubMed ID: 12973842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost determinants in aggressive non-Hodgkin's lymphoma.
    van Agthoven M; Sonneveld P; Verdonck LF; Uyl-de Groot CA
    Haematologica; 2005 May; 90(5):661-71. PubMed ID: 15921381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three measures of tumor necrosis factor alpha activity and insulin resistance in nonobese Japanese type 2 diabetic patients.
    Ohya M; Taniguchi A; Fukushima M; Nakai Y; Kawasaki Y; Nagasaka S; Kuroe A; Taki Y; Yoshii S; Hosokawa M; Inagaki N; Seino Y
    Metabolism; 2005 Oct; 54(10):1297-301. PubMed ID: 16154427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary localized stages I and II non-Hodgkin's lymphoma of the nasopharynx: a retrospective 17-year single institutional experience.
    Mohammadianpanah M; Ahmadloo N; Mozaffari MA; Mosleh-Shirazi MA; Omidvari S; Mosalaei A
    Ann Hematol; 2009 May; 88(5):441-7. PubMed ID: 18931844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
    Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.